var data={"title":"Anagrelide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Anagrelide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5644?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=anagrelide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Anagrelide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=anagrelide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Anagrelide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135406\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Agrylin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135407\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Agrylin;</li>\n      <li>Dom-Anagrelide;</li>\n      <li>Mylan-Anagrelide;</li>\n      <li>PMS-Anagrelide;</li>\n      <li>Sandoz-Anagrelide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135424\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Phosphodiesterase-3 Enzyme Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135409\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombocythemia:</b> Oral: Initial: 0.5 mg 4 times daily or 1 mg twice daily (most patients will experience adequate response at dose ranges of 1.5 to 3 mg per day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Maintain initial dose for &ge;1 week, then adjust to the lowest effective dose to reduce and maintain platelet count &lt;600,000/mm<sup>3</sup> ideally to the normal range; the dose must not be increased by &gt;0.5 mg per day in any 1 week; maximum single dose: 2.5 mg; maximum daily dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Thrombocythemia, essential (off-label dosing):</b> Oral: 0.5 mg twice daily for 1 week, then adjust dose to maintain platelet counts at normal (&le;450,000/mm<sup>3</sup>) or near normal (450,000/mm<sup>3</sup> to 600,000/mm<sup>3</sup>) levels (Gisslinger, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135418\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=anagrelide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Anagrelide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Thrombocythemia:</b> Oral: Initial: 0.5 mg once daily (range: 0.5 mg 1 to 4 times daily) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Maintain initial dose for &ge;1 week, then adjust to the lowest effective dose to reduce and maintain platelet count &lt;600,000/mm<sup>3</sup> ideally to the normal range; the dose must not be increased by &gt;0.5 mg per day in any 1 week; maximum single dose: 2.5 mg; maximum daily dose: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135410\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8112334\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135411\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate impairment (Child-Pugh score 7 to 9): Initial: 0.5 mg once daily; maintain for at least 1 week with careful monitoring of cardiovascular status; the dose must not be increased by &gt;0.5 mg per day in any 1 week. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment (Child-Pugh score &ge;10): Avoid use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135388\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Agrylin: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135374\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5172803\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135391\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Thrombocythemia: </b>Treatment of thrombocythemia associated with myeloproliferative disorders to reduce the risk of thrombosis and reduce associated symptoms (including thrombohemorrhagic events)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6884123\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Anagrelide may be confused with anastrozole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135381\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not always defined; reactions similar in adult and pediatric patients unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Palpitations (26%), edema (21%), peripheral edema (9%), chest pain (8%), tachycardia (8%), angina pectoris (1% to &lt;5%), cardiac arrhythmia (1% to &lt;5%), cardiac failure (1% to &lt;5%), hypertension (1% to &lt;5%), orthostatic hypotension (1% to &lt;5%), syncope (1% to &lt;5%), vasodilatation (1% to &lt;5%), atrial fibrillation, cardiomegaly, cardiomyopathy, cerebrovascular accident, complete atrioventricular block, decreased diastolic pressure (pediatric patients), increased heart rate (pediatric patients), myocardial infarction, pericardial effusion, systolic hypotension (pediatric patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (44%), dizziness (15%), pain (15%), malaise (6%), paresthesia (6%), amnesia (1% to &lt;5%), chills (1% to &lt;5%), confusion (1% to &lt;5%), depression (1% to &lt;5%), drowsiness (1% to &lt;5%), insomnia (1% to &lt;5%), migraine (1% to &lt;5%), nervousness (1% to &lt;5%), fatigue (pediatric patients) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (8%), pruritus (6%), alopecia (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (26%), nausea (17%), abdominal pain (16%), flatulence (10%), vomiting (10%), anorexia (8%), dyspepsia (5%), constipation (1% to &lt;5%), gastritis (1% to &lt;5%), gastrointestinal hemorrhage (1% to &lt;5%), pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (1% to &lt;5%), bruise (1% to &lt;5%), hemorrhage (1% to &lt;5%),  thrombocytopenia (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased liver enzymes (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (23%), back pain (6%), arthralgia (1% to &lt;5%), myalgia (1% to &lt;5%), muscle cramps (pediatric patients) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Diplopia (1% to &lt;5%), visual field defect (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Hematuria (1% to &lt;5%), renal failure (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (12%), cough (6%), epistaxis (1% to &lt;5%), flu-like symptoms (1% to &lt;5%), pneumonia (1% to &lt;5%), pleural effusion,  pulmonary hypertension, pulmonary fibrosis, pulmonary infiltrates </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Eosinophilic pneumonitis, hepatotoxicity, hypersensitivity pneumonitis, increased serum ALT (&gt;3 x ULN), increased serum AST (&gt;3 x ULN), interstitial nephritis, interstitial pneumonitis, leukocytosis, prolonged Q-T interval on ECG, skin photosensitivity (pediatric patients), torsades de pointes, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135394\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135378\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding risk: Major hemorrhagic events have occurred when used concomitantly with aspirin. Monitor closely for bleeding, particularly when used concurrently with other agents known to increase bleeding risk (eg, anticoagulants, NSAIDs, antiplatelet agents, other phosphodiesterase 3 (PDE) inhibitors, and selective serotonin reuptake inhibitors).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular adverse events: Ventricular tachycardia and torsades de pointes have been reported. As with other PDE3 inhibitors, anagrelide may cause vasodilation, tachycardia, palpitations and heart failure. PDE3 inhibitors are associated with decreased survival (compared to placebo) in patients with class III or IV heart failure. In a scientific statement from the American Heart Association, anagrelide has been determined to be an agent that may cause direct myocardial toxicity (magnitude: major) (AHA [Page 2016]). Dose-related increases in heart rate and mean QTc interval have been observed in a clinical trial. The maximum change in mean heart rate was ~8 beats per minute (bpm) at a dose of 0.5 mg and ~29 bpm with a 2.5 mg dose. The maximum mean change in QTc I (individual subject correlation) from placebo was 7 ms and 13 ms with doses of 0.5 mg and 2.5 mg, respectively. Do not use in patients with hypokalemia, congenital long QT syndrome, a known history of acquired QTc prolongation, or when using concomitant therapy which may prolong the QTc interval. Hypotension accompanied by dizziness may occur, particularly with higher doses. Use with caution in patients with cardiovascular disease (eg, heart failure, bradyarrhythmias, electrolyte abnormalities); consider periodic ECGs; benefits should outweigh risks. Pretreatment cardiovascular evaluation (including ECG) and careful monitoring during treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disorders: Interstitial lung disease (including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) has been associated with use. Onset is from 1 week to several years, usually presenting with progressive dyspnea with lung infiltrations; symptoms usually improve after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal abnormalities: Renal abnormalities (including renal failure) have been observed with anagrelide use; may be associated with preexisting renal impairment, although dosage adjustment due to renal insufficiency was not required. Monitor closely in patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; dosage reduction and careful cardiovascular monitoring are required for moderate impairment. Use has not been studied in patients with severe impairment. Hepatic impairment increases anagrelide exposure and may increase the risk of QTc prolongation. Monitor liver function prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135420\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135383\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8593&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: Anagrelide may enhance the adverse/toxic effect of Cilostazol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enoximone: May enhance the adverse/toxic effect of Anagrelide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milrinone: Anagrelide may enhance the adverse/toxic effect of Milrinone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Anagrelide may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135384\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135397\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Data regarding use of anagrelide during pregnancy is limited. The manufacturer recommends effective contraception in women of childbearing potential. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20536891\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if anagrelide is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135386\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Platelet count (every 2 days during the first week of treatment and at least weekly until the maintenance dose is reached; continue to monitor after cessation of treatment); CBC with differential (monitor closely during first 2 weeks of treatment), liver function (ALT and AST; baseline and during treatment), BUN, and serum creatinine (monitor closely during first weeks of treatment); serum electrolytes; blood pressure; heart rate; cardiovascular exam, including ECG (pretreatment; monitor during therapy); signs/symptoms of interstitial lung disease; monitor for thrombosis or bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135377\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Anagrelide appears to inhibit cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipase, possibly by inhibiting phospholipase A<sub>2</sub>. It also causes a dose-related reduction in platelet production, which results from decreased megakaryocyte hypermaturation (disrupts the postmitotic phase of maturation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135393\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> In pediatric patients 7-14 years; data has shown a decreased maximum serum concentration (48%) and AUC (55%) compared to adults when normalized to dose and bodyweight. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Initial: Within 7 to 14 days; complete response (platelets &le;600,000/mm<sup>3</sup>): 4 to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 6 to 24 hours; upon discontinuation, platelet count begins to rise within 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, partially via CYP1A2; to two major metabolites, RL603 and 3-hydroxy anagrelide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Food has no clinically significant effect </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Anagrelide: 1.5 hours, similar data reported in pediatric patients 7-14 years; 3-hydroxy anagrelide: 2.5 hours  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 hour, similar data reported in pediatric patients 7-14 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135396\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Agrylin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $992.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Anagrelide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $1,116.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $2,406.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135398\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agrelid (AR);</li>\n      <li>Agrylin (AU, BB, HK, ID, IL, JP, KR, PH, SG, TH, TW);</li>\n      <li>Ahrelid (UA);</li>\n      <li>Thromboreductin (AT, BG, CH, CZ, HK, HN, HR, LV, MY, PH, RO, TH, TR);</li>\n      <li>Xagrid (AT, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, LT, LU, LV, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agrylin (anagrelide) [prescribing information]. Wayne, PA: Shire US Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell PJ, Bareford D, Erber WN, et al, &ldquo;Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy,&rdquo; <i>J Clin Oncol</i>, 2009, 27(18):2991-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/19364963/pubmed\" target=\"_blank\" id=\"19364963\">19364963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doubek M, Brychtova Y, Doubek R, et al, &ldquo;Anagrelide Therapy in Pregnancy: Report of a Case of Essential Thrombocythemia,&rdquo; <i>Ann Hematol</i>, 2004, 83(11):726-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/15278298/pubmed\" target=\"_blank\" id=\"15278298\">15278298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fruchtman SM, Petitt RM, Gilbert HS, et al, &ldquo;Anagrelide: Analysis of Long-Term Efficacy, Safety and Leukemogenic Potential in Myeloproliferative Disorders,&rdquo; <i>Leuk Res</i>, 2005, 29(5):481-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/15755500/pubmed\" target=\"_blank\" id=\"15755500\">15755500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gisslinger H, Gotic M, Holowiecki J, et al, &ldquo;Anagrelide Compared With Hydroxyurea in WHO-Classified Essential Thrombocythemia: The ANAHYDRET Study, A Randomized Controlled Trial,&rdquo; <i>Blood,</i> 2013, 121(10):1720-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/23315161/pubmed\" target=\"_blank\" id=\"23315161\">23315161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrison CN, Campbell PJ, Buck G, et al, &ldquo;Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):33-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/16000354/pubmed\" target=\"_blank\" id=\"16000354\">16000354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hern&aacute;ndez-Boluda JC, Pereira A, Cervantes F, et al, &ldquo;Clinical Evaluation of the European Leukemianet Response Criteria in Patients With Essential Thrombocythemia Treated With Anagrelide,&rdquo; <i>Ann Hematol</i>, 2013, 92(6):771-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/23354997/pubmed\" target=\"_blank\" id=\"23354997\">23354997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pescatore SL and Lindley C, &ldquo;Anagrelide: A Novel Agent for the Treatment of Myeloproliferative Disorders,&rdquo; <i>Expert Opin Pharmacother</i>, 2000, 1(3):537-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/11249536/pubmed\" target=\"_blank\" id=\"11249536\">11249536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silver RT, &ldquo;Anagrelide is Effective in Treating Patients With Hydroxyurea-Resistant Thrombocytosis in Patients With Chronic Myeloid Leukemia,&rdquo; <i>Leukemia</i>, 2005, 19(1):39-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/15510207/pubmed\" target=\"_blank\" id=\"15510207\">15510207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steurer M, Gastl G, Jedrzejczak WW, et al, Anagrelide for Thrombocytosis in Myeloproliferative Disorders: A Prospective Study to Assess Efficacy and Adverse Event Profile,&rdquo; Cancer, 2004, 101(10):2239-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/15476273/pubmed\" target=\"_blank\" id=\"15476273\">15476273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tefferi A and Vardiman JW, &ldquo;Classification and Diagnosis of Myeloproliferative Neoplasms: The 2008 World Health Organization Criteria and Point-of-Care Diagnostic Algorithms,&rdquo; <i>Leukemia</i>, 2008, 22(1):14-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anagrelide-drug-information/abstract-text/17882280/pubmed\" target=\"_blank\" id=\"17882280\">17882280</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8593 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135406\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135407\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135424\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135409\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F135418\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135410\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8112334\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F135411\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135388\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135374\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5172803\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135391\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6884123\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135381\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135394\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135378\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F135420\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135383\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135384\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135397\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20536891\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135386\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135377\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135393\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F135396\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135398\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8593|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=anagrelide-patient-drug-information\" class=\"drug drug_patient\">Anagrelide: Patient drug information</a></li><li><a href=\"topic.htm?path=anagrelide-pediatric-drug-information\" class=\"drug drug_pediatric\">Anagrelide: Pediatric drug information</a></li></ul></div></div>","javascript":null}